Neuronostics
John Terry, Co-Founder and Managing Director of Neuronostics
Neuronostics has won a prize of 125,000 USD to support the further development of its patented Software-as-a-Medical-Device BioEP. The company says that BioEP is a 'ground-breaking' clinical decision support tool that can provide an objective rating of the level of support for a diagnosis of epilepsy using clinical data that is currently considered uninformative.
BioEP uses the power of mathematical modelling to interrogate recordings of the brain’s electrical activity (EEG) that are routinely collected from people who are suspected of having epilepsy. In over 70% of cases the test is clinically inconclusive resulting in delays, uncertainty and cost, as well as have a significant impact on quality of life for people with suspected epilepsy. BioEP can address some of these challenges, providing additional information to help prioritise workload, determine most appropriate next steps and impact confidence in clinical decision-making.
Inspired by the American equivalent of Dragon’s Den, the Epilepsy Foundation Shark Tank Competition attracts entrepreneurs, scientists, and clinicians from around the world who are developing novel approaches to address the challenges of epilepsy. Four other finalists from Portugal, France and the US competed alongside Neuronostics from a pool of approaching 50 applicants.
Five Sharks representing clinicians, venture capital and the patient voice grilled each team on the science behind their ideas and their commercial plan, as well as the potential of the technology to meaningfully impact people with epilepsy and their families. Each Shark got to award 25,000 USD, with a vote from the watching audience determining a further 75,000 USD in prize money. Following an animated debate, Neuronostics secured the support of 2 Sharks as well as taking the audience vote to secure total prize money of 125,000 USD.
John Terry, Co-Founder and Managing Director of Neuronostics who pitched BioEP in the competition said: “We are delighted to have received this recognition from the Epilepsy Foundation. Having regulated BioEP with the MHRA, we are excited to bring the product to the NHS during 2025. This win further demonstrates the potential for BioEP to meaningfully benefit the 500,000 Americans who are suspected of having epilepsy each and every year. Speaking with many attendees afterwards it was clear that our pitch had made waves and it was fantastic that we got a couple of sharks to bite!”
“Receiving an award at Shark Tank isn’t just about the prize,” said Caitlin Grzeskowiak, Vice President Research and Innovation, Epilepsy Foundation. “It's a testament to Neuronostics team to showcase these significant technological advancements past what currently exists for the epilepsy community. We are incredibly proud of what they’ve accomplished and look forward to continued collaboration. I know this technology can make a real difference for many living with epilepsy.”
Neuronostics plans to use the prize funding to accelerate the development of its technology, with the goal of securing approval from the U.S. Food and Drug Administration (FDA) that will enable the launch of BioEP in the US market during 2026.
